This Ciena Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Analysts initiated coverage: Buy on FORM ($200), NUVB ($12); Outperform on CIEN ($440); Neutral on EXPD ($180); Equal-Weight on SFD ($22).
Stocks · News reference
Nuvation Bio Announces New Subgroup Analyses From Pivotal TRUST-I And TRUST-II Studies Evaluating IBTROZI In Both TKI- Naïve And TKI-Pretreated Patients With Advanced ROS1+ NSCLC
Long-term pooled data from the pivotal TRUST-I and TRUST-II studies showed similar efficacy, including duration of response and progression-free survival, between CD74 and non-CD74 ROS1 fusion-partner subgroupsAmong
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citigroup Initiates Coverage On Nuvation Bio with Buy Rating, Announces Price Target of $12
Citigroup analyst Geoff Meacham initiates coverage on Nuvation Bio (NYSE:NUVB) with a Buy rating and announces Price Target of $12.
Nuvation Bio shares are trading higher after the company announced the FDA approval of its sNDA for IBTROZI with updated duration of response in TKI-naïve advanced ROS1-positive non-small cell lung cancer.
Why Is Nuvation Bio Stock Gaining Thursday?
Nuvation Bio (NUVB) stock jumps 6% after early FDA label update for IBTROZI, highlighting over 4 years of clinical benefit in ROS1+ NSCLC.